吉西他滨联合卡培他滨治疗晚期三阴乳腺癌的临床研究

目的探讨吉西他滨联合卡培他滨治疗晚期三阴乳腺癌（TNBC）的临床疗效及毒性反应情况。方法40例TNBC患者给予吉西他滨联合卡培他滨治疗方案，吉西他滨1g／m2静脉滴注，d1、8；卡培他滨1g／m2口服，2次／d，d1～d14。以上治疗方案3w为1个周期。化疗前给予地塞米松、格拉司琼止吐，化疗4个周期后评价临床疗效及毒性反应。结果本组完全缓解（cR）2例，部分缓解（PR）16例，稳定（sD）14例，进展（PD）8例，总有效率（RR）为45．0％。所有患者均随访至2012年12月，失访3例，中位肿瘤进展时间（TTP）为6．1个月。主要毒性反应包括骨髓抑制、手足综合征，次要毒性反应包括腹泻、恶心、呕吐、口腔炎、发热和脱发。结论吉西他滨联合卡培他滨治疗TNBC近期效果满意，毒性反应可耐受。

Clinical Researches on the Effects of Gemcitabine Combined with Capecitabine for Advanced Triple-Negative Breast Cancer Treatment

Objective To investigate the clinical effects and occurrence of toxic reactions of gemcitabine combined with capecitabine in the treatment of advanced triple-negative breast cancer （TNBC）. Methods Forty patients with TNBC were treated with gemcitabine combined with capecitabine. Intravenous injection of 1 g/m2 gemcitabine was given on dl and dS,whereas 1 g/mz capecitabine was taken orally from dl to dl4,twice a day. The therapeutic regimen above lasted for 3 weeks was considered as one course of treatment. Dexamethasone and granisetron were given to stop vomiting before chemotherapy. After 4 cycles of chemotherapy,the clinical effects and toxic reactions were evaluated. Results In this group,there were 2 cases of complete remission （CR）, 16 cases of partial remission （PR）, 14 cases of stable disease （SD）, 8 cases of progression of disease （PD）, and the total remission rate （RR） was 45.0%. All patients except 3 patients were given follow-up visit till December, 2012. Their tumor medial time to progression （TTP） was 6.1 months. The primary toxic reactions included myelosuppression and hand-foot syndrome, and secondary ones included diarrhea, nausea, vomiting, stomatitis, fever and alopecia. Conclusion The short-term therapeutic effect of gemcitabine combined with capecitabine in the treatment of TNBC is satisfactory,and toxic reactions can be tolerated.